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Background: A number of RNA viruses cause viral hemorrhagic fever (VHF), in which proinflammatory mediators
released from infected cells induce increased permeability of the endothelial lining of blood vessels, leading to loss
of plasma volume, hypotension, multi-organ failure, shock and death. The optimal treatment of VHF should
therefore include both the use of antiviral drugs to inhibit viral replication and measures to prevent or correct
changes in vascular function. Although rodent models have been used to evaluate treatments for increased
vascular permeability (VP) in bacterial sepsis, such studies have not been performed for VHF.
Results: Here, we use an established model of Pichinde virus infection of hamsters to demonstrate how changes
in VP can be detected by intravenous infusion of Evans blue dye (EBD), and compare those measurements to
changes in hematocrit, serum albumin concentration and serum levels of proinflammatory mediators. We show
that EBD injected into sick animals in the late stage of infection is rapidly sequestered in the viscera, while in
healthy animals it remains within the plasma, causing the skin to turn a marked blue color. This test could be used
in live animals to detect increased VP and to assess the ability of antiviral drugs and vasoactive compounds to
prevent its onset. Finally, we describe a multiplexed assay to measure levels of serum factors during the course of
Pichinde arenavirus infection and demonstrate that viremia and subsequent increase in white blood cell counts
precede the elaboration of inflammatory mediators, which is followed by increased VP and death.
Conclusions: This level of model characterization is essential to the evaluation of novel interventions designed to
control the effects of virus-induced hypercytokinemia on host vascular function in VHF, which could lead to
improved survival.
Background
A number of RNA viruses in the filovirus, bunyavirus,
arenavirus and flavivirus families cause a syndrome of
fever, increased vascular permeability (VP), shock and
hemorrhage in humans that is designated viral hemor-
rhagic fever (VHF). In most cases, alterations in vascular
function is attributed to the release of cytokines and
other permeability factors that destabilize the endothe-
lial barrier, causing plasma volume loss that leads to
hypovolemic shock, multi-organ failure, and death [1,2].
In the clinical setting, an increase in the hematocrit
(HCT) is a marker for increased VP [3]. Because serum
albumin is a highly abundant small molecular-weight
protein, it may be particularly prone to diffusing out of
plasma in situations of increased VP [4].
Although much effort has been devoted to developing
drugs to directly block viral replication in VHF, counter-
measures to address increases in VP have not been eval-
uated. With the exception of dengue virus infection in
mice deficient in interferon response pathways [5,6],
animal models to evaluate novel therapeutics to reverse
endothelial vascular leakage have not been established.
To develop VHF models of vascular leakage, it is neces-
sary to establish methods to measure the process in
living animals during the course of infection, as a means
to evaluate the effects of agents employed to reduce the
permeability of the endothelial cell lining.
For nearly a century, the intravenous infusion of Evans
blue dye (EBD) has been a highly useful tool for evaluat-
ing blood volume [7,8]. Recent studies have employed
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albumin with a high affinity, and thus leakage of plasma
into the extravascular space can be determined during
necropsy by removing organs and extracting the dye.
The major limitation of this test is that, because the
nimals must be sacrificed, it can only be performed
o n c ed u r i n gt h ec o u r s eo fi l l n e s s .An o n - i n v a s i v et e s t
for increased VP that could be used in conjunction with
experimental therapies would be ideal to gauge the
effects of a specific treatment.
An important consideration for modeling VHF is the
need for a well-characterized system in which to evaluate
the relationship between infection, viremia, the elaboration
of proinflammatory mediators, increased VP, changes in
intravascular volume and death. Although investigators
have described a number of small animal models that
reproduce various aspects of human VHF [10], none have
examined vascular leakage in the context of the sequential
events that lead to the death of the animals. Here we use a
modified EBD procedure to detect increased VP and assess
its connection with disease severity in a hamster model of
arenaviral HF. We also validate the assay by demonstrating
vascular leakage in hamsters infected with yellow fever
virus. Having determined that the EBD assay can reveal
increased VP during the course of acute arenaviral infec-
tion, we then assess whether changes in HCT and albu-
min, which can be measured in live animals, correlate with
the timing of increased VP as shown by the EBD method.
We also demonstrate for the first time, at the protein
level, the hypercytokinemia induced by arenavirus infec-
tion in a hamster HF model.
Methods
Animals
Female golden Syrian hamsters were obtained from
Charles River Laboratories (Wilmington, MA) and accli-
mated to the Laboratory Animal Research Facility at
Utah State University for 3-6 days prior to use. Animals
were ~6-8 weeks of age at time of challenge. All animal
procedures complied with USDA guidelines and were
approved by the Utah State University Institutional Ani-
mal Care and Use Committee.
Viruses
Pichinde virus (PICV), strain An 4763, was provided by
Dr. David Gangemi (Clemson University, Clemson, SC).
The hamster-adapted Jimenez strain of yellow fever
virus (YFV) was obtained from Dr. Robert Tesh (World
Reference Center for Emerging Viruses and Arboviruses,
University of Texas Medical Branch, Galveston, TX).
The viruses were passed once through hamsters and
stocks made from pooled hamster liver homogenates.
Stocks were diluted in minimal essential medium
( M E M ,H y c l o n e ,L o g a n ,U T )j u s tp r i o rt oi n f e c t i o u s
challenge (0.2 ml) by the intraperitoneal (i.p.) route.
Assessment of vascular leakage
VP was determined by intravenous administration of
EBD (Sigma-Aldrich, St. Louis, MO) and tracking its dif-
fusion into various tissues. At designated times following
infection, hamsters were anesthetized with isoflurane and
injected retro-orbitally with a 0.5% EBD PBS solution.
Retro-orbital injections were given using a 27-gauge
needle by carefully inserting the tip ~1 mm from the out-
ermost edge of the eye into the membrane exposed by
gently pulling the skin away from the eye. Once the
membrane has been penetrated, the solution is slowly
injected to allow for rapid absorption by the capillary
nexus at that site. The retro-orbital intravenous injection
method has been compared to tail vein delivery in mice
and found to be equally effective [11]. The amount of
E B Di n j e c t e dw a sb a s e do nb o d yw e i g h tw i t ha n i m a l s
receiving ~18 mg/kg of dye (0.4 ml for a 110 g hamster).
After a 4 h period, blood was collected in sacrificed ani-
mals by cardiac puncture, and the vasculature was exten-
sively perfused transcardially with PBS to remove
residual blood. Tissue sections of liver, spleen, lung, kid-
ney and small intestine were harvested, weighed, and
immersed in 0.5 ml of formamide for EBD extraction
from tissue samples by overnight incubation at 37°C.
A 0.1 ml volume from each sample tube was placed into
a 96-well microtiter plate, and the absorbance at 610 nm
was measured. Relative EBD content in the serum was
determined from 1:10 diluted samples measured at
610 nm and 740 nm. The absorbance at 740 nm was sub-
tracted from the 610 nm absorbance values to deduct the
contributions from hemoglobin contamination. Data are
expressed as a ratio of absorbance per g of tissue:absor-
bance of the diluted respective serum sample.
Hematocrit (HCT), white blood cell (WBC), and other
hematologic parameter analysis
Anticoagulated whole blood samples taken from ham-
sters were evaluated on a VetScan® HMT analyzer
( A b a x i s ,U n i o nC i t y ,C A )t oa s s e s sH C T ,W B C ,a n d
other parameters. At designated times following infec-
tion, groups of hamsters were anesthetized with isoflur-
ane for retro orbital venous sinus blood collection
(~0.5 ml) or sacrificed for blood draw by cardiac punc-
ture. Only HCT was evaluated in the YFV system. PICV
studies included the analysis of WBC, red blood cells
( R B C ) ,a n dh e m o g l o b i n( H b )f r o mr e p e a t e db l o o d
collection during the infection.
Blood chemistry
Sera collected on day 7 of PICV infection from two
independent experiments (n = 10) were stored at -80°C
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Inc., Union City, CA) was used to determine blood
chemistry values. The Comprehensive Diagnostic Profile
reagent rotor was selected for quantitative determination
of 14 parameters (ALB, ALP, ALT, AMY, BUN, CA
++,
CRE, GLOB, GLU, K
+,N A
+,P H O S ,T B I L ,T P )
described in the footnotes of Table 1. For comparison,
serum samples from 6 sham-infected hamsters from the
same two experiments were also analyzed.
Serum albumin measurement
Sera obtained from a time course study of PICV infec-
tion in hamsters were analyzed for albumin content
u s i n gt h eA l b u m i nR e a g e n tS e tf r o mP o i n t eS c i e n t i f i c
(Canton, MI) per the manufacturer’s recommendations.
The assay was adapted for use in 96-well microtiter
plates by adjusting the reagent volumes. Albumin stan-
dard was also obtained from Pointe Scientific.
Multi-cytokine, chemokine, and serum factor analysis
Serum samples from PICV-infected and sham-infected
groups of hamsters were sent to Rules-Based Medicine,
Inc. (RBM, Austin, Texas) for analysis of 58
biomarkers on the RodentMAP® version 2.0 platform
(Additional file 1, Figure S1), which employs micro-
spheres impregnated with fluorescent dyes and coated
with reagents that bind with target substances in
serum and plasma. Using this technology, RBM can
analyze a large number of serum factors in less than
50 μL of serum. Although the RodentMAP® is only
validated for mouse samples, we have previously
observed that antibody cross-reactivity enables the sys-
tem to measure relative levels of a number of hamster
proteins (B. Gowen, unpublished data). Nevertheless,
the absence of measurable changes in certain cytokines
or factors in our analysis of hamster samples may be
due to limited cross-reactivity, and not necessarily a
lack of involvement. The least detectable dose (LDD)
is defined as 3 standard deviations above mean back-
ground measured for each analyte in each multiplex. If
an analyte’s value is below the LDD but still falls on
the calibration curve, the value is reported. These
values are likely real, but the precision of these values
are decreased when they fall below the LDD.
Results
Measurement of increased VP in PICV-infected hamsters
Our initial goal was to test the hypothesis that increased
VP is associated with severe PICV infections in ham-
sters. To this end, we modified a previously described
method used in mice based on the tracking of EBD [5]
injected i.v. through the tail vein to measure systemic
leakage into various tissues. First, hamsters had to be
infused by the retro-orbital route. To control the ani-
mal-to-animal variation that may be associated with
EBD-PBS injected retro-orbitally, we modified the pro-
cedure to normalize our measurements of tissue EBD
concentrations by dividing each tissue value by the
serum EBD concentration. As shown in Figure 1A, a
significant increase in the tissue/serum EBD ratio for
liver, spleen, lung, and kidney were observed in PICV-
infected animals on day 7, relative to sham-infected con-
trols. A dramatic difference in blue coloration is evident
upon gross examination of the internal organs, with the
lungs of PICV-infected animals showing a striking blue
coloration, compared to those of healthy controls
(Figure 1B). Moreover, the data obtained from the EBD
extractions from the tissues shown in Figure 1B support
the visual evidence that increased VP is associated with
advanced stage PICV infection in hamsters, while the
EBD serum content was typically higher in uninfected
than in PICV-infected hamsters. For example, in the
animal shown in Figure 1B, the serum EBD concentra-
tion was 34% less in the infected animal than in the
sham-infected control, consistent with the leakage of
dye into the viscera. Remarkably, in contrast to infected
animals, the skin of healthy hamsters turned blue within
Table 1 Mean blood chemistry values from sham- or
PICV-challenged hamsters on day 7 of infection
a
Analyte Sham-infected PICV-infected P-value
b
ALB (g/dL) 5.2 ± 0.2 4.0 ± 0.3 ***
ALP (U/L)
c 180 ± 27 > 1914 ± 606 ***
ALT (U/L)
d 160 ± 74 > 1894 ± 213 ***
AMY (U/L) 1659 ± 408 690 ± 227 ***
TBIL (mg/dL) 0.23 ± 0.05 0.62 ± 0.61 NS
BUN (mg/dL) 25.8 ± 1.7 24.2 ± 13.4 NS
Ca
++ (mg/dL) 14.2 ± 0.6 13.2 ± 0.8 *
PHOS (mg/dL) 10.6 ± 0.6 8.2 ± 1.0 ***
CRE (mg/dL)
e < 0.25 ± 0.05 < 0.38 ± 0.12 *
GLU (mg/dL) 183 ± 30 80 ± 37 ***
Na
+ (mM) 148 ± 4 149 ± 4 NS
K
+ (mM)
f > 8.5 ± 0.0 > 8.4 ± 0.1 NS
TP (g/dL) 6.3 ± 0.1 6.3 ± 0.4 NS
GLOB (g/dL) 1.1 ± 0.3 2.3 ± 0.5 ***
aSham-infected, n = 6; PICV-infected, n = 10.
bStudent’s two-tailed t-test. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not
significant.
cThree PICV-infected hamsters had saturated levels of ALP (> 2400 U/L).
dSeven PICV-infected hamsters had saturated levels of ALT (> 2400 U/L).
eOne PICV- and three sham-infected hamsters had levels below the limit of
detection (0.2 mg/dL)
fSeven PICV- and six sham-infected hamsters had saturated levels of K
+ (8.5
mM).
Bold font indicates analytes differing significantly between sham- and PICV-
infected hamsters.
ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY,
amylase; TBIL, total bilirubin; BUN, blood urea nitrogen; Ca
++, calcium; PHOS,
phosphate; CRE, creatinine; GLU, glucose; Na
+, sodium; K
+, potassium; TP, total
protein; GLOB, globulin.
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Page 3 of 13Figure 1 Evidence of increased vascular permeability during late-stage PICV infection in hamsters.A )T w og r o u p so fa n i m a l s( n=6 /
group) were infected with ~5 plaque-forming units of PICV or sham (MEM vehicle). On day 7 of infection, EBD-PBS was injected retro-orbitally
and the ratio of EBD concentration in the kidney, liver, lung and spleen to the serum EBD concentration was evaluated. Data are expressed as
the ratio of absorbance/g of tissue:absorbance of the diluted matching serum sample. *P < 0.05, **P < 0.01 compared to sham-infected hamsters
by the Mann-Whitney test (two-tailed). B) Images taken of kidneys, livers (single lobes), lungs, and spleens harvested from a sham-infected
control and a PICV-infected hamster on day 7. The serum concentration of EBD was 34% greater in the sham-infected control compared to the
infected animal. On the right, images of the respective hamsters’ mouths and front paws are included to show the stronger blue coloration
notable in the uninfected animal. Dye was extracted from the kidneys, livers, lungs, and spleens shown and the EBD content data are
represented in the associated graph.
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retention of the dye within the vascular system.
Time course analysis of VP during PICV infection
Studies aimed at resolving the timeframe in which
increased VP occurs in the hamster PICV infection
model are essential to inform future studies in which
the initiation of treatment may be triggered by the onset
of vascular leakage. To this end, we conducted an
experiment to gauge vascular leakage during the acute
infection in hamsters. A statistically significant increase
in the ratio of tissue:serum EBD concentration was seen
on day 7 following PICV challenge in the spleen and on
day 8 in the liver, spleen, and lungs (Figure 2). Notably,
the animal that had lost the most weight in the day-8
sacrifice group (data not shown) had the highest levels
of EBD in liver, kidney and lung, but not spleen tissue.
Based on the previous experiment, (Figure 1A), we
had expected to see a greater increase in vascular leak
on day 7 in liver and lung. However, it is important to
note that one animal in each of the last two sacrifice
groups (day 7 and 8) succumbed to the infection after
EBD-PBS administration (day 7 hamster) or prior to the
day of sacrifice (day 8 hamster). Because the data
Figure 2 Analysis of vascular permeability during PICV infection in hamsters. Groups of animals were infected with ~5 plaque-forming
units of PICV, with the exception of 4 hamsters that were processed at the time of infection to establish the day 0 baseline reading. On each
day of the infection (days 1-8), a group of animals was injected retro-orbitally with EBD-PBS and vascular leak into the (A) liver, (B) spleen, (C)
kidney, and (D) lung tissues was evaluated. Data are expressed as the ratio of absorbance/g of tissue:absorbance of the diluted matching serum
sample. For days 1-6, there were 5 hamsters/group. Days 7 and 8 had 6 animals/group, but due to the death of one animal in each group prior
to time of sacrifice, the analysis is based on 5 hamsters for these groups. *P < 0.05, **P < 0.01 compared to day 0 animals using one-way
analysis of variance (ANOVA) with the Newman-Keuls multiple comparison test.
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they probably underestimate the vascular leakage for
those groups. This fact, and experimental variability
comparing samples harvested on different days, could
account for the less pronounced increase in VP that we
observed in this study.
Longitudinal analysis of WBC, HCT, and other
hematologic parameters during PICV infection
Increased circulating levels of WBC, reflecting their mobili-
zation from the bone marrow, are a reliable indicator of
viral infection. We previously showed that in PICV-
infected hamsters, virus becomes detectable in the circula-
tion on day 5 of infection [12]. Consistent with this finding,
we observed an increase in the WBC count starting on day
6 and remaining high through day 8 (Figure 3A).
We also tracked changes in HCT in PICV-infected
hamsters. We anticipated seeing an increase in HCT,
reasoning that as vascular leakage occurs there would be
an increase in the packed cell volume due to plasma
volume loss, but probably because daily samples were
collected from individual animals on days 0, 2, and 4-8,
the HCT actually dropped slightly over the course of
the infection (Figure 3B). Because one infected animal
died on day 7 and one on day 8, the mean HCT values
on those days may be underestimated.
The main objective of this experimental approach was
to determine whether the HCT could serve as a marker
for VP over the course of illness. Because frequent blood
collection led to anemia, as determined by the RBC
count and hemoglobin content (Figure 3C, D), we also
conducted a study in which we collected blood samples
only on days 6 and 7 of infection, which coincides with
the transition to loss of vascular integrity by the EBD
method. In the day 6 samples (3 sham- and 5 PICV-
infected), the HCT was significantly higher in the sham-
infected animals (data not shown), similar to the trend
seen in the earlier blood sampling study (Figure 3B). On
day 7, there was no significant difference between the
sham- and PICV-infected hamsters (data not shown). It
is possible that RBC loss from the intravascular compart-
ment in infected animals may be occurring through
extravasation into tissues. We investigated this possibility
by histological analysis of liver, lung, and spleen sections
harvested on day 7 of infection but did not see evidence
of RBC loss by this mechanism (data not shown). Our
findings, and that previously reported for Pirital arena-
virus infection in hamsters [13], indicate that changes in
the HCT do not directly reflect alterations in VP.
Blood chemistry analysis and reduced serum albumin as
a marker for vascular leakage
Because the binding of EBD to albumin is the basis of
the test for vascular leak, we reasoned that changes in
the serum albumin concentration might be used to
track alterations in VP. We therefore performed a blood
chemistry analysis to assess its utility in hamsters. As
shown in Table 1, the serum albumin level was signifi-
cantly reduced in PICV-infected hamsters on day 7,
compared to the sham-infected controls.
Previously, evidence of decreased albumin levels in
VHF hamster models based on infection with the related
Pirital arenavirus [13] and YFV [14,15] has been
reported. Having observed dramatically reduced serum
albumin levels in the PICV-infected animals, we further
evaluated the possibility of using this analyte as a non-
terminal indicator of vascular perturbation. A more
rapid and cost-effective assay was employed to specifi-
cally evaluate serum albumin concentration during the
course of PICV infection. As observed in Figure 4,
serum albumin levels drop significantly by day 4 and
remained low through the end of the 7-day sampling
period. Although there are differences in the g/dL
amounts estimated by the two albumin detection meth-
ods (VetScan VS2 analyzer and Pointe Scientific Albu-
min Reagent Set), clear differences relative to the
respective controls were observed.
Blood chemistry analysis also revealed a number of
other changes during PICV infection (Table 1). As
expected, concentrations of the liver-associated enzymes
ALP and ALT were extremely high in the infected ani-
mals. Amylase was markedly decreased, as were calcium,
phosphate, and glucose levels. It is conceivable that the
decrease in glucose levels is due to a reduction in food
consumption as the animals become sick and perhaps
because the liver and pancreas are diseased and mal-
functioning. Pancreatic insufficiency would explain the
lower amylase concentrations. Also as expected, globulin
levels were significantly elevated on day 7, which is
generally one day before the hamsters begin to succumb.
Profiling of hamster serum cytokines, chemokines and
other serum factors during PICV infection
In severe viral infections, hypercytokinemia triggers the
changes in VP that lead to leakage of plasma into the
extravascular spaces and circulatory collapse. In the pre-
sent study and elsewhere [12], we have demonstrated
t h es e q u e n c eo fv i r e m i ab e g i n n i n go nd a y5o fP I C V
infection, followed by the appearance of elevated WBC
on day 6, and transition to vascular leakage on day 7
and 8. In order to determine whether proinflammatory
mediators could play a causative role in this process, we
analyzed serum from sham- and PICV-infected hamsters
on days 0, 2, and 4-7. As shown in Figure 5, there was a
substantial increase from day 5 to 6 in many of the
cytokines and chemokines examined, preceding the
increase in VP measure by the EBD method (Figure 2).
Interestingly, IL-1a and MIP-2 showed a reversal in the
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the course of infection.
Of the non-cytokine/chemokine factors evaluated,
three were altered during the infection (Additional file 2,
Figure S2). Fibrinogen, an acute phase protein, was mark-
edly elevated from baseline values of ~200 μg/ml through
the first 5 days of infection, up to ~30,000 to 70,000 μg/
ml on days 6 and 7. Consistent with previously reported
data [12], aspartate aminotransferase (AST) concentra-
tion, a prognostic indicator of disease outcome in human
cases of Lassa fever [16], increased gradually over time
with a spike on day 6. Also dramatically increased
beginning on day 6 after infection was Von Willebrand
factor (vWF).
Analysis of vascular leakage in hamsters infected with
YFV
To investigate whether another established hamster
model of VHF would show evidence of increased VP
measured by the transfer of EBD from serum to the
internal organs, YFV-infected hamsters were evaluated
from 3-7 days post infection to assess the possible devel-
opment of vascular leak. A significant increase in the
ratio of tissue to serum EBD concentration was seen in
Figure 3 Longitudinal hematologic analysis of PICV infection in hamsters. Two groups of hamsters were infected with ~5 plaque-forming
units of PICV or sham-infected. On each of days 0, 2, and 4-8 of the infection, blood was collected by retro-orbital venous sinus route following
isoflurane anesthesia for hematologic analysis as described in the methods section. The data points represent the analysis of samples from
groups of 4 hamsters with the exception of the PICV-infected group, wherein due to the death of a single animal in the on day 7, and a second
hamster on day 8, the data reflect values for 3 and 2 animals, respectively, for days 7 and 8. (A) White blood cells, WBC, (B) hematocrit, HCT,
(C) red blood cells, RBC, and (D) hemoglobin, Hb values are shown. m/mm
3, millions per cubic milliliter of blood.
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ning on day 6 and continuing through day 7 (Figure 6A,
D). Clear indication of EBD leakage into spleen and kid-
ney tissue was not observed (Figure 3B, C). Previously,
slightly increased HCT levels on day 5 of YFV infection
in hamsters have been reported [17,18]. In the present
study, the HCT similarly increased slightly on days 5
and 6, but the difference compared to sham-infected
controls was not statistically significant (Figure 3E). No
change in HCT was seen on day 7, when the most pro-
minent change in EBD concentration in the liver and
small intestine of infected animals was observed,
suggesting that factors other than VP are affecting the
HCT.
Discussion
This report marks the first attempt to assess changes in
vascular barrier function during acute infections in ham-
sters that model VHF. Vascular barrier function is con-
trolled through inter-endothelial cell contacts made, for
example, of adherens junctions such as vascular
endothelial cadherin (VE-cadherin) [19]. Under normal
conditions, these junction proteins adequately regulate
fluid leak through strong homophilic contacts. However,
during pathologic settings such as VHF, when the vas-
cular barrier is responding to exaggerated and sustained
signals promoting increased VP, the result is excessive
edema accumulation, hypotension, and ultimately death.
A si st h ec a s ef o ro t h e rd i s e a s e ss u c ha ss e p s i sa n d
pandemic influenza, VHF influences vascular barrier
function through increased levels of circulating cyto-
kines. These mediators negate VE-cadherin function,
leading to vascular hyperpermeability, multiorgan edema
and failure, non-cardiogenic shock and death. Here, we
use the transfer of EBD from the plasma into the viscera
as a marker to demonstrate that viremia leads to
increased cytokine levels, followed by enhanced VP, in
the PICV hamster model of arenaviral HF. Significant
accumulation of EBD indicative of vascular hyperperme-
ability in both the PICV and YFV models precedes mor-
tality, suggesting that platforms that enhance vascular
stability may be an excellent therapeutic system to target
late stage events seen during disease progression.
We evaluated different methods of detecting changes in
VP in the PICV hamster infection model. Further, we
report the first profiling of systemic protein levels of a
large number of cytokines, chemokines, and other serum
factors in the PICV hamster model. The data provide
insights into the contribution of the excessive proinflam-
matory response that induces vascular hyperpermeability
associated with VHF and sepsis. This type of understand-
ing supports the use of this model system to study anti-
viral therapies and pathophysiology, and it brings to
focus issues associated with drug delivery during
advanced disease wherein compromised drug absorption
p r o f i l e sm a yb eo b s e r v e dw h e nd o s i n gb yr o u t e so f
administration commonly used in animal experiments
(i.p., i.m., and s.c.). Challenges still lie ahead in regards to
the evaluation of therapeutic approaches aimed at pre-
venting increases in VP in the face of a severe viral infec-
tion. The major hurdle is the lack of a good marker of
vascular hyperpermeability that can be measured in live
animals to assess the impact of a candidate therapy on
correcting the problem.
The present study describes our efforts to identify
markers of increased VP in a hamster model of acute
arenaviral infection. Our findings do not support the
use of the HCT as a measure of vascular leakage in the
hamster PICV infection models. Because we did not
monitor water consumption of individual hamsters, it is
possible that the animals continued to drink sufficient
amounts of water, thereby limiting the elevation in HCT
at the later stages of infection. However, we don’t
believe that this occurred, because the animals began to
lose weight on day 7, suggesting that water and food
intake was greatly reduced. In addition, there was no
evidence of RBC loss due to extravasation into viscera
of infected hamsters. There may also be some intravas-
cular hemolysis occurring as the serum total bilirubin
levels are increased, but not statistically significantly.
This increase in total bilirubin has also been noted dur-
ing Pirital arenavirus infection in hamsters [13]. It is
also possible that alterations in normal kidney function
Figure 4 Serum albumin levels during the course of PICV
infection in hamsters. Groups of hamsters were infected with ~5
plaque-forming units of PICV and serum was obtained following
sacrifice on days 1, and 3-7 of PICV infection. Samples were assayed
for albumin concentration. Data represent the means and standard
deviations of 3-4 hamsters per group. *P < 0.05, **P < 0.01
compared to day 0 animals using ANOVA with the Newman-Keuls
multiple comparison test.
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Page 8 of 13Figure 5 Analysis of systemic levels of inflammatory mediators during PICV infection in hamsters. Groups of animals (n = 3-4/group)
were infected with ~5 plaque-forming units of PICV, with the exception of 3 hamsters that were processed at the time of infection to establish
the day 0 baseline reading. On each of days 2, and 4-7 of the infection, serum was collected from PICV-infected hamsters for multi-analyte
profiling of serum antigens. Data are shown for hamster cytokines and chemokines that were sufficiently cross-reactive with the Rodent MAP®
detection platform and changed significantly over the course of infection. The least detectable dose is indicated by the red hashed line and is
defined in the methods. GCP, Granulocyte Chemotactic Protein; IL, Interleukin; IP, Inducible Protein; MCP, Monocyte Chemoattractant Protein;
M-CSF, Macrophage-Colony Stimulating Factor; MDC, Macrophage-Derived Chemokine; MIP, Macrophage Inflammatory Protein; SCF, Stem Cell
Factor; VCAM, Vascular Cell Adhesion Molecule; VEGF, Vascular Endothelial Cell Growth Factor.
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Page 9 of 13Figure 6 Analysis of vascular permeability and HCT during YFV infection in hamsters. Groups of animals were infected with ~20 cell
culture infectious doses (CCID50) of YFV or sham-infected. On specified days of the infection (days 3-7), groups of YFV-infected hamsters (n = 5)
and groups of sham-infected animals (n = 3) were injected retro-orbitally with EBD following collection of whole blood for evaluation of HCT.
Vascular leak into the (A) liver, (B) spleen, (C) kidney, and (D) small intestine tissues, and (E) HCT were evaluated. Vascular permeability data are
expressed as the ratio of absorbance/g of tissue:absorbance of the diluted matching serum sample. SI, sham-infected. *P < 0.05, ***P < 0.001
compared to the pool of sham-infected animals using ANOVA with the Newman-Keuls multiple comparison test.
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Page 10 of 13due to infection may reduce the production of erythro-
poietin, thereby curtailing RBC production and masking
hemoconcentration. Collectively, the potential contribu-
tions of multiple factors do not make HCT a good mar-
ker for measuring VP in PICV-infected hamsters.
A low serum albumin concentration was also consid-
ered as a marker for increased VP. However, the fact
that albumin levels decreased significantly by day 4 fol-
lowing PICV challenge, while serum cytokine levels
were still normal, indicates that, as in the case of HCT,
the serum albumin concentration is influenced by
factors other than VP. By the current “gold standard” of
measuring EBD leakage, we do not see evidence of
vascular perturbation until day 7 and 8 of PICV infec-
tion. The apparent dissociation with drop in albumin
and changes in VP may be due to decreased hepatic
synthesis of albumin as a result of altered liver function
in PICV-infected animals. This possibility is supported
by previously published data showing 5 log10 of liver
v i r u sb u r d e ns t a r t i n go nd a y2t h r o u g h4o fi n f e c t i o n ,
with 6 log10 of virus by day 5, and 8 log10 by day 6 [12].
Notably, with the YFV model, serum albumin drops sig-
nificantly on days 5 and 6 of infection [14,15], which is
more proximal to the time at which we observed
evidence of vascular leak (day 6 in the liver and day 7 in
the small intestine) by the EBD method.
Measurement of the tissue/serum EBD ratio would
appear to be the best method of assessing the effect of an
experimental therapy aimed at countering increased VP.
Our normalization of the data through the conversion of
EBD concentration into a tissue/serum ratio controls for
animal-to-animal variability in dosing, and provides a
more meaningful determination of the transfer of dye
from the serum into the organs than the tissue concentra-
tion alone. At the same time, the retention of EBD within
the vascular system of healthy animals, causing their skin
to develop a strong blue color, serves as a readily visible
marker of normal vascular function. The degree of blue
Figure 7 Natural history of disease in hamster PICV infection model. The schematic shown is a summary of the present data integrated with
previously published findings [12]. Two days after challenge, the presence of PICV in the liver, kidney, spleen, and lung is evident. On day 3, the
type I IFN response is measurable and fluctuates slightly over the duration of the acute infection. On days 4 and 5, a significant drop in serum
albumin and the first signs of systemic PICV burden, respectively, are observed. By day 6, infectious PICV can be detected in the brain, ALT and AST
enzyme levels rise, and WBC and proinflammatory mediators dramatically increase. Day 7 marks the onset of vascular leak, peak viral titer, ALT, and
AST concentrations, and initial signs of weight loss. Eight days after challenge, significant vascular leakage is present in multiple tissues, with some
animals beginning to succumb and showing clear signs of illness. The majority of the hamsters will succumb by day 9 of infection.
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Page 11 of 13coloration of the skin could thus be scored semi-quantita-
t i v e l yo nas c a l eo f0t o4a taf i x e dt i m ea f t e rE B Di n f u -
sion, with a low score indicating the development of
i n c r e a s e dV P .B e c a u s et h ed y ei sn o tt o x i ca tt h ed o s e s
used and is cleared very slowly from the circulation, ani-
mals could be monitored continually to evaluate vascular
function. However, one must consider any possible effects
of EBD on the model system, drug-dye interactions, and
the fact that in a few cases, EBD has been shown to have
antiviral activity in vitro [20-22].
Our studies of PICV and YFV infection of hamsters
suggest that these models reproduce the vascular leak-
age that plays a key role on the pathogenesis of VHF
leading to vascular collapse [1,23]. In the PICV hamster
infection model, the basic features of VHF in humans
are demonstrated through the sequence of viremia,
followed by excessive release of inflammatory mediators,
vascular hyperpermeabilitya n dd e a t h( F i g u r e7 ) .T h e s e
models therefore offer an opportunity to propose and
test new therapeutic strategies, including those that pre-
vent or correct the increase in VP that is associated
with severe disease and death in VHF [2,24]. Strategies
aimed at reducing viremia or immunomodulation con-
tinue to dominate. As other models of VHF are charac-
terized with a focus on the timing and pathologic events
between infection and death, we may find that an
approach based on blunting the effects of excessive
inflammatory mediators on vascular function may
provide the basis for a broad based strategy to treat
multiple infectious challenges [19,25].
Additional material
Additional file 1: Figure S1: Rodent MAP® antigens. Complete 58
antigen panel of the version 2.0 Rodent MAP® system validated for
interrogation of mouse serum or plasma samples. Sufficient cross
reactivity of hamster factors allows for detection and measurement of
relative levels for many of the antigens.
Additional file 2: Figure S2: Changes in systemic levels of
fibrinogen, AST, and vWF during PICV infection in hamsters. Groups
of animals (n = 3-4/group) were infected with ~5 plaque-forming units
of PICV, with the exception of 3 hamsters that were processed at the
time of infection to establish the day 0 baseline reading. On each of
days 2, and 4-7 of the infection, serum was collected from PICV-infected
hamsters for multi-analyte profiling of serum antigens. Data are shown
for non-cytokine/chemokine factors that were sufficiently cross-reactive
with the Rodent MAP® detection platform and changed significantly over
the course of infection. The least detectable dose is indicated by the red
hashed line and is defined in the methods. AST, aspartate
aminotransferase; vWF, Von Willebrand factor.
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